Correlation between NT-proBNP and SYNTAX score of STEMI patients

doi:10.3877/cma.j.issn.2095-5782.2020.03.013

Abstract

Abstract:

Objective

To analyze the relationship between NT-proBNP and SYNTAX score of STEMI patients.

Methods

The clinical data of STEMI patients (n=105) admitted to the Fifth Affiliated Hospital of Sun Yat-sen University from January 2019 to December 2019 were retrospectively analyzed. The SYNTAX scores were calculated according to CAG results for 105 STEMI patients who underwent percutaneous coronary intervention (PCI). All patients were divided into three groups ccording to the SYNTAX score: low-SS group, mid-SS group and high-SS group, and the relationship between NT-proBNP and SYNTAX score were evaluated.

Results

The average age of 105 STEMI patients (92 male and 13 female) was 55.10±11.67 years (range29-84years). According to the SYNTAX score, there were 18 cases in low-SS group, 38 cases in mid-SS group, and 49 cases in thigh-SS group. There was no significant difference in the baseline clinical characteristic between three groups. But there were significant differences in LVEF, NT-proBNP, cTnI, AST, LDH, α-HBD, CK, CK-MB between three groups (P<0.05). The results of Pearson correlation analysis showed that NT-proBNP was positively correlated to SYNTAX (r=0.223, P=0.022).

Conclusions

The level of NT-proBNP is tightly related to cardiac function and can be taken into consideration for decision-making among PCI in STEMI patients.

Key words: ST-segment elevation acute myocardial infarction, SYNTAX score, NT-proBNP

Lizi Jin, Ani Wang, Tingting Su, Junyong Han, Fang Zhou, Bairong Chen. Correlation between NT-proBNP and SYNTAX score of STEMI patients[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2020, 08(03): 252-255.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2020.03.013

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2020/V08/I03/252

Figures/Tables 4

References 11

[1]	Moran AE, Forouzanfar MH, Roth GA, et al. The global burden of ischemic heart disease in 1990 and 2010[J]. Circulation,2014, 129(14): 1493-1501.
[2]	Roth GA, Forouzanfar MH, Moran AE, et al. Demographic and epidemiologic drivers of global cardiovascular mortality[J]. New England Journal of Medicine, 2015, 372(14): 1333-1341.
[3]	Chakravarty T, Buch MH, Naik H, et al. Predictive accuracy of SYNTAX score for predicting long-term outcomes of unprotected left main coronary artery revascularization[J]. The American Journal of Cardiology, 2011, 107(3): 360-366.
[4]	Kim Y, Park D, Kim W, et al. Validation of SYNTAX(synergy between PCI with taxus and cardiac surgery)score for prediction of outcomes after unprotected left main coronary revascularization[J]. JACC: Cardiovascular Interventions, 2010, 3(6): 612-623.
[5]	Redfors B, Chen S, Crowley A, et al. B-type natriuretic peptide assessment in patients undergoing revascularization for left main coronary artery disease[J]. Circulation, 2018, 138(5): 469-478.
[6]	Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[J]. European Heart Journal, 2018, 39(2): 119-177.
[7]	Zhang Y, Yang S, Liu X, et al. Management of ST-segment elevation myocardial infarction in predominantly rural central China[J]. Medicine, 2016, 95(49): e5584.
[8]	Richards AM. N-terminal B-type natriuretic peptide in heart failure[J]. Heart Failure Clinics, 2018, 14(1): 27-39.
[9]	Chen WW, Gao RL, Liu LS, et al. China cardiovascular diseases report 2015: A summary[J]. J Geriatr Cardiol, 2017, 14(1): 1-10.
[10]	Kario K, Chen C, Park S, et al. Consensus document on improving hypertension management in Asian patients, taking into account Asian characteristics[J]. Hypertension, 2018, 71(3): 375-382.
[11]	Zhang C, Jiang L, Xu L, et al. Implications of N-terminal pro-B-type natriuretic peptide in patients with three-vessel disease[J]. European Heart Journal, 2019, 40(41): 3397-3405.

?	低分组（n/N，%）	中分组（n/N，%）	高分组（n/N，%）	P值
年龄	52.00±11.00	56.29±9.89	55.31±13.12	0.68
性别（男）	17/18(94.4%)	33/38(86.8%)	42/49(85.7%)	0.62
吸烟史（有）	11/18(61.1%)	21/38(55.3%)	34/49(69.4%)	0.40
高血压病史（有）	6/18(33.3%)	18/38(47.4%)	16/49(32.7%)	0.34
糖尿病史（有）	3/18(16.7%)	7/38(18.4%)	11/49(22.4%)	0.83
冠心病家族史（有）	1/18(5.6%)	3/38(7.9%)	2/49(4.1%)	0.75

?	低分组（n/N，%）	中分组（n/N，%）	高分组（n/N，%）	P值
年龄	52.00±11.00	56.29±9.89	55.31±13.12	0.68
性别（男）	17/18(94.4%)	33/38(86.8%)	42/49(85.7%)	0.62
吸烟史（有）	11/18(61.1%)	21/38(55.3%)	34/49(69.4%)	0.40
高血压病史（有）	6/18(33.3%)	18/38(47.4%)	16/49(32.7%)	0.34
糖尿病史（有）	3/18(16.7%)	7/38(18.4%)	11/49(22.4%)	0.83
冠心病家族史（有）	1/18(5.6%)	3/38(7.9%)	2/49(4.1%)	0.75

?	低分组（N=18例）	中分组（N=38例）	高分组（N=49例）	P值
WBC（×10^9/L）	11.65±3.42	11.72±3.87	12.41±3.98	0.33
HGB（g/L）	144.06±11.33	135.81±19.57	141.12±21.04	0.99
PLT（×10^9/L）	244.06±60.37	251.03±77.60	241.45±63.82	0.98
BUN（mmol/L）	4.62±1.60	5.28±2.50	5.46±1.93	0.06
Cr（umol/L）	70.72±17.88	83.59±47.28	74.59±20.33	0.56
eGFR（mi/min/1.73m²）	101.41±15.83	91.04±22.01	95.51±17.44	0.43
TG（mmol/L）	1.99±0.96	1.76±0.94	1.47±0.45	0.06
TC（mmol/L）	5.02±1.34	4.81±1.38	5.06±1.22	0.58
HDL-C（mmol/L）	0.96±0.23	0.93±0.19	1.00±0.22	0.36
LDL-C（mmol/L）	3.04±0.99	3.00±1.02	3.26±0.97	0.21
FBG（mmol/L）	6.44±2.24	6.82±3.01	6.70±2.17	0.29
HbAlc（%）	6.20±1.00	6.35±1.65	6.23±1.35	0.28
NT-proBNP （pg/mL）	929.83±1046.64	1 818.29±2 181.04	2 495.37±2 835.22	0.007
cTnI（ug/L）	13.63±8.31	15.16±9.38	18.17±9.28	0.02
AST（ug/L）	172.33±161.78	228.55±182.44	366.51±271.86	0.001
LDH（ug/L）	477.83±314.23	570.13±386.32	860.12±604.00	0.002
α-HBD（ug/L）	464.33±333.66	554.92±386.32	830.92±599.42	0.003
CK（ug/L）	2 023.89±1 896.17	2 383.21±2 019.22	4 127.90±3 372.31	0.002
CK-MB（ug/L）	174.90±178.38	183.85±167.04	289.87±219.14	0.004
LVDD（mm）	47.81±3.62	47.79±5.08	48.90±5.14	0.35
LVEF（%）	63.63±8.03	62.26±7.63	56.60±12.39	0.005

?	低分组（N=18例）	中分组（N=38例）	高分组（N=49例）	P值
WBC（×10^9/L）	11.65±3.42	11.72±3.87	12.41±3.98	0.33
HGB（g/L）	144.06±11.33	135.81±19.57	141.12±21.04	0.99
PLT（×10^9/L）	244.06±60.37	251.03±77.60	241.45±63.82	0.98
BUN（mmol/L）	4.62±1.60	5.28±2.50	5.46±1.93	0.06
Cr（umol/L）	70.72±17.88	83.59±47.28	74.59±20.33	0.56
eGFR（mi/min/1.73m²）	101.41±15.83	91.04±22.01	95.51±17.44	0.43
TG（mmol/L）	1.99±0.96	1.76±0.94	1.47±0.45	0.06
TC（mmol/L）	5.02±1.34	4.81±1.38	5.06±1.22	0.58
HDL-C（mmol/L）	0.96±0.23	0.93±0.19	1.00±0.22	0.36
LDL-C（mmol/L）	3.04±0.99	3.00±1.02	3.26±0.97	0.21
FBG（mmol/L）	6.44±2.24	6.82±3.01	6.70±2.17	0.29
HbAlc（%）	6.20±1.00	6.35±1.65	6.23±1.35	0.28
NT-proBNP （pg/mL）	929.83±1046.64	1 818.29±2 181.04	2 495.37±2 835.22	0.007
cTnI（ug/L）	13.63±8.31	15.16±9.38	18.17±9.28	0.02
AST（ug/L）	172.33±161.78	228.55±182.44	366.51±271.86	0.001
LDH（ug/L）	477.83±314.23	570.13±386.32	860.12±604.00	0.002
α-HBD（ug/L）	464.33±333.66	554.92±386.32	830.92±599.42	0.003
CK（ug/L）	2 023.89±1 896.17	2 383.21±2 019.22	4 127.90±3 372.31	0.002
CK-MB（ug/L）	174.90±178.38	183.85±167.04	289.87±219.14	0.004
LVDD（mm）	47.81±3.62	47.79±5.08	48.90±5.14	0.35
LVEF（%）	63.63±8.03	62.26±7.63	56.60±12.39	0.005

?	SS评分
?	r值	P值
NT-proBNP（pg/mL）	0.223	0.022
LVEF（%）	-0.316	0.001

Please choose a citation manager

Content to export